CLINICAL CHEMISTRY AND LABORATORY MEDICINE, cilt.49, sa.1, ss.93-97, 2011 (SCI-Expanded)
Background: Evidence suggests that zinc-alpha(2)-glycoprotein (ZAG) might serve as a biomarker for human metabolic alterations. We measured serum ZAG in patients with nonalcoholic fatty liver disease (NAFLD), a hepatic manifestation of the metabolic syndrome, and examined its association with clinical, biochemical, and histological phenotypes.